Correction
Small molecule enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2-mediated microRNA processing
Paper Information
Record ID:
66767
Author(s):
Journal:
Publication Date:
February 28, 2011
Retraction Date:
February 14, 2025
(<1 year years ago)
Subjects:
Institutions:
- Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, 08908 L'Hospitalet, Barcelona, Catalonia, Spain
- Translational Research Laboratory, Catalan Institute of Oncology, Bellvitge Biomedical Research Institute, 08908 L'Hospitalet Barcelona, Catalonia, Spain
- Departments of Experimental Therapeutics and Cancer Genetics, M D Anderson Cancer Center, Houston, TX 77030
- Bioinformatics Core Facility, CH-1015 Lausanne, Switzerland
- Department of Pathology, Hospital Universitari de Bellvitge, Bellvitge Biomedical Research Institute, 08907 L'Hospitalet de Llobregat, Barcelona, Spain
- Departamento de Bioquímica y Biología Molecular, Universidad de Alcalá, Alcalá de Henares, 28801 Alcalá de Henares, Madrid, Spain
- Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215
- Department of Molecular Virology, Immunology and Medical Genetics and Comprehensive Cancer Center, Ohio State University, Columbus, OH 43210
- Institucio Catalana de Recerca i Estudis Avançats, 08010 Barcelona, Catalonia, Spain
Countries:
Article Type:
Publisher:
National Academy of Sciences (NAS)
Open Access:
Yes
PubMed ID:
Retraction PubMed ID:
Correction Details
Citations (0)
0
Total Citations0
Post-Retraction0
Pre-Retraction0
Same Day
No citations found for this paper.
Related Records
This article has multiple records in the database due to different notices:
Record #20088
Jan 17, 2017Quick Stats
Total Citations:
0
Years Since Retraction:
<1 year
Open Access:
Yes
Last Checked:
Never